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Objective: To explore the completeness of tumor, node, metastasis (TNM) staging for colon 
and rectal cancer in the Danish Cancer Registry.
Material and methods: From the Danish Cancer Registry, we retrieved data on TNM stage, 
year of diagnosis, sex, and age for 15,976 and 8292 patients, respectively, with first diagnoses 
of colon or rectal cancer during the 2004–2009 period. From the Danish National Patient 
Register, we retrieved data on comorbidity (computed as Charlson Comorbidity Index scores). 
We calculated the completeness of TNM staging overall, by each stage component, and according 
to a stage algorithm allowing some missing stage components. Analyses were stratified by sex, 
age, year of diagnosis, and Charlson Comorbidity Index score.
Results: For colon and rectal cancer, overall TNM completeness was 67.8% (95% confidence 
interval [CI]: 67.0%–68.5%) and 68.1% (95% CI: 67.0%–69.1%), respectively. For both can-
cers, completeness decreased with increasing age and level of comorbidity, whereas differences 
between the sexes were minor. Over the study period, TNM completeness for colon cancer 
decreased from 71.3% (95% CI: 69.5%–73.0%) to 64.8% (95% CI: 63.0%–66.6%), whereas 
the completeness for rectal cancer remained stable over time. When using the stage algorithm, 
the completeness rose markedly, to 81.1% for colon cancer and 79.0% for rectal cancer.
Conclusion: One-third of colon and rectal cancer cases in the Danish Cancer Registry had 
missing TNM stage information, which varied with age and level of comorbidity. Cancer cases 
with unknown staging warrant serious consideration of the methodological implications in future 
epidemiological studies monitoring cancer incidence and outcomes.
Keywords: colorectal neoplasm, neoplasm staging, TNM, registries, epidemiology, cancer
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth 
most common cause of cancer-related death.1 Tumor stage is a key determinant of CRC 
prognosis and provides guidance to the optimal planning of treatment. Furthermore, 
the stage is important for monitoring trends in CRC incidence and mortality across 
populations. The tumor, node, metastasis (TNM) stage classification is based on the 
anatomic extent of the tumor, including the tumor size (T), the number of lymph nodes 
involved (N), and the presence of metastases (M).2
Since 1943, all incident cancers in Denmark have been recorded in the Danish 
Cancer Registry (DCR).3,4 Reporting to the DCR has been mandatory since 1987, and 
ascertainment of cancer cases in the registry is virtually complete.3–5 TNM staging 
has been recorded for cancer cases since 2004.4 However, no studies have hitherto 
examined the completeness of TNM staging in the DCR. Some studies have suggested 
that factors such as age, race, sex, marital status, income, and residence influence the 
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proportion of unstaged cancers.6–8 Given that information 
on TNM might not be missing at random, unstaged CRCs 
could bias results of studies monitoring cancer incidence 
and outcomes. We therefore aimed to evaluate the complete-
ness of CRC staging in the DCR according to the TNM 
classification – overall, and by sex, age, year of diagnosis, 
and level of comorbidity.
Methods
We performed this study in Denmark, within a population of 
5.4 million inhabitants. The Danish National Health Service 
provides free medical care by general practitioners and hos-
pitals. All health-related services are registered with a unique 
ten-digit personal identifier – the CPR number – assigned 
since 1968 to each resident.9 This number allows unambiguous 
individual-level data linkage between Danish registers.
Ascertaining patients with CRC
We used the DCR to identify patients with a primary 
diagnosis of CRC between January 1, 2004 and December 
31, 2009. During this period, the DCR recorded cancer 
diagnoses according to the International Classification of 
Disease, 10th revision (ICD-10).3,4 Colon and rectal cancer 
cases were identified by the ICD-10 codes C18 and C19–20, 
respectively. From the DCR, we also obtained information 
on CPR number, date of diagnosis, age, sex, and TNM stage 
at diagnosis.
Comorbidity data
The Danish National Patient Register contains data on all 
nonpsychiatric discharges from hospitals in Denmark since 
1977 and all outpatient visits since 1995.10 Information 
includes CPR number, date of contact/discharge, and diag-
noses according to ICD-10 since 1994. From the Danish 
National Patient Register, we obtained information on pre-
existing comorbidity 10 years prior to the date of CRC diag-
nosis using a modified version of the Charlson Comorbidity 
Index (CCI). The CCI is based on disease categories that 
are each weighted according to the adjusted risk of one-year 
mortality.11,12 Excluding CRC from the index, we defined the 
level of comorbidity as low (CCI score = 0), medium (CCI 
score = 1–2), and high (CCI score $ 3).
Statistical analysis
We calculated the completeness of TNM stage registration and 
the corresponding 95% confidence intervals (CIs), both over-
all and for each component individually (ie, T, N, and M). The 
completeness was defined as the number of individuals with 
no missing factors (ie, T1–4, N0–3, and M0–1) divided by the 
total number of patients. We stratified completeness by sex, 
age (0–39 years, 40–59 years, 60–79 years, and $ 80 years), 
year of colon or rectal cancer diagnosis, and CCI score.
Complete information on T, N, and M is necessary to 
derive a definite TNM stage in the DCR. For additional 
categorization of colon or rectal cancers into localized, 
regional, distant, or unknown stages, we designed an algo-
rithm, allowing certain missing stage components, under the 
assumption that the remaining information was sufficient to 
provide a meaningful categorization (eg, cancers assigned 
T4, Nx, M1 in the DCR were categorized as “distant”; see 
Appendix 1). The algorithm was based on knowledge of 
tumor growth and clinical coding practice In addition, we 
restricted the analysis to histologic verified CRC cases.
Analyses were performed using SAS (v 9.2; SAS Insti-
tute, Inc, Cary, NC).
Results
Colon cancer
A total of 15,976 patients were diagnosed with colon cancer 
during the 2004–2009 period (Table 1). Females accounted for 
51.5% of the colon cancer cases, with a median age at diagnosis 
of 74 years. The median age for men was 72 years. Overall 
TNM completeness was 67.8% (95% CI: 67.0%–68.5%) 
(Table 1). Examining each stage component, the overall regis-
tration proportion was slightly higher for M (83.5% [95% CI: 
82.9%–84.0%]) than for T (80.3% [95% CI: 79.7%–80.9%]) 
and N (76.4% [95% CI: 75.8%–77.1%]) (Table 2). We found 
that 93.3% of the colon cancer cases were histologically 
verified. Restricting to this proportion, overall TNM was 70.8% 
(95% CI: 70.1%–71.5%).Differences in TNM completeness 
between the sexes were minor, with males exhibiting a slightly 
higher completeness than females. Completeness of the TNM 
staging decreased with (1) increasing age, from 68.5% (95% 
CI: 61.2%–75.1%) in patients ,40 years to 57.0% (95% CI: 
55.5%–58.5%) in patients $ 80 years; (2) year of diagnosis, 
from 71.3% (95% CI: 69.5%–73.0%) in 2004 to 64.8% (95% 
CI: 63.0%–66.6%) in 2009; and (3) level of comorbidity, 
from 70.8% (95% CI: 69.9%–71.7%) in patients with lowest 
comorbidity (CCI score = 0) to 57.2% (95% CI: 54.8%–59.5%) 
among those with high level of comorbidity (CCI score $ 3) 
(Table 1). Using the algorithm for stage classification (Appen-
dix 1), we found that 5473 (34.3%) of the colon cancers were 
localized, whereas regional and distant cases accounted for 
3463 (21.7%) and 4022 (25.2%), respectively. A total of 3018 
(18.9%) colon cancers were not classifiable according to the 
algorithm (data not shown).
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Table 1 TNM completeness for colon and rectal cancer; overall and by sex, age, year, and comorbidity
Colon Cancer Rectal cancer
Total TNM completeness Total TNM completeness
No. No. % (95% CI) No. No. % (95% CI)
Overall 15,976 10,824 67.8 (67.0–68.5) 8292 5643 68.1 (67.0–69.1)
Sex
Female 8233 5534 67.2 (66.2–68.2) 3341 2180 65.3 (63.6–66.9)
Male 7743 5290 68.3 (67.3–69.4) 4951 3463 70.0 (68.7–71.2)
Age
#39 years 168 115 68.5 (61.2–75.1) 63 65 78.3 (68.6–86.1)
40–59 years 2327 1737 74.6 (72.9–76.4) 1667 1266 75.9 (73.9–78.0)
60–79 years 9262 6568 70.9 (70.0–71.8) 4926 3517 71.4 (70.1–72.7)
$ 80 years 4219 2404 57.0 (55.5–58.5) 1616 795 49.2 (46.8–51.6)
Year of diagnosis
2004 2555 1822 71.3 (69.5–73.0) 1339 930 69.5 (67.0–71.9)
2005 2615 1782 68.1 (66.3–69.9) 1284 858 66.8 (64.2–69.4)
2006 2704 1885 69.7 (68.0–71.4) 1417 962 67.9 (65.4–70.3)
2007 2656 1802 67.9 (66.1–69.6) 1371 950 69.3 (66.8–71.7)
2008 2706 1757 64.9 (63.1–66.7) 1442 938 65.1 (62.6–67.5)
2009 2740 1776 64.8 (63.0–66.6) 1439 1005 69.8 (67.4–72.2)
Comorbiditya
Low 9617 6806 70.8 (69.9–71.7) 5464 3903 71.4 (70.2–72.6)
Medium 4706 3073 65.3 (63.9–66.7) 2192 1409 64.3 (62.3–66.3)
High 1653 945 57.2 (54.8–59.5) 636 331 52.0 (48.2–55.9)
Notes: aLevel of comorbidity according to the Charlson comorbidity index (CCI) score; Low (CCI score = 0), Medium (CCI score = 1–2), High (CCI score $ 3).
Abbreviations: CI, confidence interval; TNM, tumor, node, metastasis.
Table 2 T, N, and M completeness for colon cancer; overall and by sex, age, year, and comorbidity
Total T completeness N completeness M completeness
No. No. % (95% CI) No. % (95% CI) No. % (95% CI)
Overall 15,976 12,831 80.3 (79.7–80.9) 12,212 76.4 (75.8–77.1) 13,334 83.5 (82.9–84.0)
Sex
Female 8233 6611 80.3 (79.4–81.2) 6257 76.0 (75.1–76.9) 6802 82.6 (81.8–83.4)
Male 7743 6220 80.3 (79.4–81.2) 5955 76.9 (76.0–77.8) 6532 84.4 (83.5–85.2)
Age (in years)
#39 168 134 79.8 (73.2–85.3) 128 76.2 (69.3–82.2) 141 83.9 (77.8–88.9)
40–59 2327 1966 84.5 (83.0–85.9) 1914 82.3 (80.7–83.8) 2081 89.4 (88.1–90.6)
60–79 9262 7655 82.7 (81.9–83.4) 7324 79.1 (78.2–79.9) 7950 85.8 (85.1–86.5)
$ 80 4219 3076 72.9 (71.6–74.2) 2846 67.5 (66.0–68.9) 3162 75.0 (73.6–76.2)
Year of diagnosis
2004 2555 2205 86.3 (84.9–87.6) 2082 81.5 (80.0–83.0) 2141 83.8 (82.3–85.2)
2005 2615 2191 83.8 (82.3–85.2) 2074 79.3 (77.7–80.8) 2141 81.9 (80.4–83.3)
2006 2704 2223 82.2 (80.7–83.6) 2132 78.9 (77.3–80.4) 2242 82.9 (81.5–84.3)
2007 2656 2104 79.2 (77.6–80.7) 2016 75.9 (74.3–77.5) 2225 83.8 (82.3–85.1)
2008 2706 2048 75.7 (74.0–77.3) 1960 72.4 (70.7–74.1) 2265 83.7 (82.3–85.1)
2009 2740 2060 75.2 (73.5–76.8) 1948 71.1 (69.4–72.8) 2320 84.7 (83.3–86.0)
Comorbiditya
Low 9617 7965 82.8 (82.1–83.6) 7589 78.9 (78.1–79.7) 8242 85.7 (85.0–86.4)
Medium 4706 3690 78.4 (77.2–79.6) 3511 74.6 (73.4–75.8) 3822 81.2 (80.1–82.3)
High 1653 1176 71.1 (68.9–73.3) 1112 67.3 (65.0–69.5) 1270 76.8 (74.8–78.8)
Notes: aLevel of comorbidity according to the Charlson comorbidity index (CCI) score; Low (CCI score = 0), Medium (CCI score = 1–2), High (CCI score $ 3).
Abbreviations: CI, confidence interval; T, tumour; N, node; M, metastasis.
Rectal cancer
Of the 8,292 rectal cancer patients diagnosed during the 
study period (Table 1), 40.3% were female with a median 
age at diagnosis of 71 years. Median age for men was 69 
years. Overall, TNM was complete for 68.1% (95% CI: 
67.0%–69.1%) of the rectal cancer cases. M was the most 
complete stage component (84.8% [95% CI: 84.0%–85.6%]), 
T completeness was close to that of M (84.0% [95% CI: 
83.2%–84.8%]), but N completeness was considerably lower 
(72.9% [95% CI: 72.0%–73.9%]) (Table 3). Restricting to 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
35
Colon and rectal cancer staging in the Danish Cancer RegistryClinical Epidemiology 2012:4 (Suppl 2)
the 95.3% of the rectum cancer cases that were histologically 
verified left the overall TNM completeness nearly unchanged   
(69.6% [95% CI: 70.8%–71.5%]). TNM completeness was 
slightly higher in males compared with females and decreased 
with increasing age, from 78.3% (95% CI: 68.6%–86.1%) 
in patients ,40 years to 49.2% (95% CI: 46.8%–51.6%) in 
patients $ 80 years. Also, TNM completeness declined with 
comorbidity level, from 71.4% (95% CI: 70.2%–72.6%) 
in patients with lowest comorbidity to 52.0% (95% CI: 
48.2%–55.9%) in patients with a high comorbidity level. 
TNM completeness did not vary by year of diagnosis 
(Table 1). According to our stage algorithm, 2569 (31.0%) 
rectal cancers were localized, 2350 (28.3%) were regional, 
and 1633 (19.7%) were distant. For a total of 1740 (21.0%) 
rectal cancer cases, the TNM stage could not be assessed 
based on the available information (data not shown).
Discussion
To our knowledge, this nationwide population-based study is the 
first to evaluate the completeness of TNM registration of CRC in 
the DCR. Although the ascertaining of cancer diagnoses in the 
DCR is virtually complete,3–5 we found that approximately one-
third of CRC patients had missing data on TNM classification. 
In particular, completeness declined with increasing age and 
level of comorbidity. Using a clinically based stage algorithm, 
we showed that the proportion of staged cases rose markedly.
The completeness of CRC staging in the US Surveillance, 
Epidemiology, and End Results, or SEER, database appears 
to be higher than what we observed in the DCR. Worthington 
et al reported that only 5.1% of colon and 7.8% of rectal can-
cers were unstaged during the 1991–2002 period.8 However, 
the SEER summary stage is computed using an algorithm that 
allows staging with one or two missing stage components. 
Although we also designed a stage algorithm that allowed 
some missing stage information, it might differ from the SEER 
template. Thus, the completenesses of TNM staging in the US 
and Danish registers is probably not directly comparable.
We found that TNM completeness varied substantially by 
age and level of comorbidity, which is in accordance with pre-
vious US studies.6–8,13,14 In a study examining the proportion 
of unstaged disease at 18 cancer sites, Merill et al reported a 
steep increase with age.6 Likewise, marital status, race, sex, 
and prognosis of the cancers influenced staging. Koroukian 
et al reported that patients with more comprehensive needs 
for care (as measured by dependence of home health care 
and nursing home care) were two to five times as likely to be 
unstaged, compared with patients with fewer needs.13
TNM completeness for colon cancer in the DCR 
decreased slightly during the study period, whereas rectal 
cancer staging remained stable over time. In contrast, a 
number of studies have reported a decrease in the propor-
tion of patients with unstaged CRCs over recent years.6–8 In 
Table 3 T, N, and M completeness for rectal cancer; overall and by sex, age, year, and comorbidity
Total T completeness N completeness M completeness
No. No. % (95% CI) No. % (95% CI) No. % (95% CI)
Overall 8292 6964 84.0 (83.2–84.8) 6048 72.9 (72.0–73.9) 7032 84.8 (84.0–85.6)
Sex
Female 3341 2739 82.0 (80.7–83.3) 2354 70.5 (68.9–72.0) 2762 82.7 (81.4–83.9)
Male 4951 4225 85.3 (84.3–86.3) 3694 74.6 (73.4–75.8) 4270 86.3 (85.3–87.2)
Age (in years)
#39 83 73 88.0 (79.7–93.6) 69 83.1 (74.0–90.0) 76 91.6 (84.2–96.2)
40–59 1667 1483 89.0 (87.4–90.4) 1338 80.3 (78.3–82.1) 1515 90.9 (89.4–92.2)
60–79 4926 4285 87.0 (86.0–87.9) 3765 76.4 (75.2–77.6) 4275 86.8 (85.8–87.7)
$ 80 1616 1123 69.5 (67.2–71.7) 876 54.2 (51.8–56.6) 1166 72.2 (69.9–74.3)
Year of diagnosis
2004 1339 1167 87.2 (85.3–88.9) 998 74.5 (72.2–76.8) 1121 83.7 (81.7–85.6)
2005 1284 1081 84.2 (82.1–86.1) 926 72.1 (69.6–74.5) 1086 84.6 (82.5–86.5)
2006 1417 1201 84.8 (82.8–86.6) 1035 73.0 (70.7–75.3) 1221 86.2 (84.3–87.9)
2007 1371 1158 84.5 (82.5–86.3) 1014 74.0 (71.6–76.2) 1173 85.6 (83.6–87.3)
2008 1442 1156 80.2 (78.1–82.2) 1007 69.8 (67.4–72.2) 1205 83.6 (81.6–85.4)
2009 1439 1201 83.5 (81.5–85.3) 1068 74.2 (71.9–76.4) 1226 85.2 (83.3–87.0)
Comorbiditya
Low 5464 4711 86.2 (85.3–87.1) 4163 76.2 (75.1–77.3) 4749 86.9 (86.0–87.8)
Medium 2192 1793 81.8 (80.1–83.4) 1512 69.0 (67.0–70.9) 1806 82.4 (80.8–83.9)
High 636 460 72.3 (68.8–75.7) 373 58.7 (54.8–62.4) 477 75.0 (71.5–78.3)
Notes: aLevel of comorbidity according to the Charlson comorbidity index score (CCI); Low (CCI score = 0), Medium (CCI score = 1–2), High (CCI score $ 3).
Abbreviations: CI, confidence interval; T, tumour; N, node; M, metastasis.
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2004, the DCR computerized and automated the registration 
of incident cancer cases, facilitating fast notifications from 
clinicians. A potential negative consequence is that the cancer 
cases might be reported before the clinical workup has been 
finalized. However, considering the number of initiatives aim-
ing to improve cancer control, including the implementation 
of Danish National Cancer Plans in 2000 and 2005,15,16 and 
the establishment of a comprehensive CRC database by the 
Danish Colorectal Cancer Group in 2001,19 one would have 
expected improvements in the registration of TNM stage 
over the study period.
A main strength of this study is its population-based 
design within the setting of a uniform tax-supported health 
care system, largely eliminating selection bias. Our study 
population was identified from updated nationwide registers. 
Although coding errors on CRC diagnoses and comorbidi-
ties cannot be ruled out, data from the DCR and the Danish 
National Patient Register have been found very complete 
and highly valid.3,5,12
Our study also had limitations. The completeness and 
accuracy of CRC diagnoses in the automated version 
of DCR (from 2004 on) have not been specifically vali-
dated. Moreover, we had no information on the underly-
ing reasons for the missing information on TNM stages 
in the DCR, although plausible explanations include 
incomplete reporting and genuine difficulties on the part 
of the clinician or pathologist in determining the stage 
of the particular cancer case. For example, patients who 
initially received oncological therapy might not have been 
registered with complete details on TNM. We found that 
the most vulnerable patients were least likely to undergo 
staging, suggesting cessation of diagnostic procedures, 
including lymph node status, if fragility did not allow 
further treatment. We also observed that approximately 
6% of CRC diagnoses were not histologically verified. 
However, although it might be expected that the majority 
of non-histologically verified cases pertained to patients 
with high comorbidity, restriction of the study population 
to histologically verified CRC cases yielded results quite 
similar to those presented.
The DCR is a valuable source for cancer research and 
statistics. Despite the high level of completeness of the 
diagnoses in this registry, we found that one-third of CRC 
patients had missing TNM-stage information, although the 
proportion of unstaged cases declined markedly with our use 
of a clinically based stage algorithm. However, complete-
ness varied differentially with age and level of comorbidity, 
indicating that TNM data are not missing at random. This 
finding warrants serious consideration of the methodological 
implications in future epidemiological studies on cancer 
incidence and survival.
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Appendix  1  Algorithm  for  colorectal  cancer  (CRC)  staging 
according to the TNM classification
Tumor stage TNMa
Localized T1–4,x N0 M0 
T1–2 N0 Mx 
T1 Nx M0,x
Regional T1–4,x N1–2 M0
Distant T1–4,x N0–2,x M1
Unknownb T2–4,x Nx M0,x 
T3–4,x N0 Mx 
T1–4,x N1–2 Mx
Notes: aIn all, 466 CRC cases were assigned N3 (categorized as N2 in the algorithm); 
bThirty CRC cases were assigned T0, Ta, or Tis (categorized as unknown stage in 
the algorithm).
Abbreviation: TNM, tumor, node, metastasis.
Appendix 1
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